Calendar

The webinar will highlight the potential challenges in cGVHD management and review of the pivotal study data, follow up data and product profile of REZUROCK.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Abeona Therapeutics.

Prademagene Zamikeracel (pz-cel) Pre-Approval Information Exchange and Clinical Trial Data.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP Market Insights Webinar.

Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care for multiple sclerosis (MS). This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in December 2024. Presenters will examine unmet patient needs in MS, the disease’s underlying pathogenesis, advancements in treatment, and payer perspectives on therapeutic value and evolving diagnostic approaches.

An AMCP Member-only Webinar.

The AMCP Research Institute launched the RWE Initiative in 2024 to develop RWE standards that will facilitate efficient communication and ensure that RWE meets expectations and needs of formulary decision-makers. In this webinar, three speakers will engage in an interactive panel to discuss the importances and relevance of RWE, to describe the multi-stakeholder process for developing the standards through expert consensus, insights on how to apply the standards, and describe ongoing efforts to build a training program to support adoption of RWE in managed care.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Sanofi.

During this webinar, the burden of disease in patients with hemophilia A and B, with or without inhibitors, the role of thrombin in hemostasis, and the efficacy and safety results from the ATLAS clinical development program will be discussed. An overview of the mechanism of action of the antithrombin lowering agent will also be presented. There will be a live Q&A to allow for interactive discussion.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP Webinar, hosted by Formulary Decisions® 

Join us for an interactive, engaging, and informative discussion as we dive into the evolving landscape of pre-approval information exchange (PIE). Our diverse panel of biopharma and market access and communication experts will guide you through a live session filled with valuable insights and strategies for engaging healthcare decision-makers with pre-approval information. We will explore opportunities and innovative solutions for leveraging PIE when collaborating with stakeholders.

A Science & Innovation Webinar, presented by Abbvie.

Psoriasis is a chronic, inflammatory, immunologic condition that primarily manifests on the skin, the body’s largest organ. If not properly treated, uncontrolled psoriasis can induce inflammatory processes beyond the skin and may lead to comorbid disease. Comorbidities that may impact psoriasis patients such as psoriatic arthritis (PsA), cardiovascular disease, metabolic syndrome, inflammatory bowel disease (IBD), depression and others add burden to the entire healthcare system and adversely impact patient outcomes.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by UroGen Pharma, Inc.

This webinar will be hosted by UroGen Pharma, Inc. and will discuss the disease state, product profile, commercialization plans, and clinical information for UGN-102. An investigational drug in development for the treatment of low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) in adult patients. The safety and efficacy of UGN-102 have not been established by the FDA. This presentation is intended for payors, formulary committees, and similar entities only.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.